Samar began her career in basic research in private and hospital settings, before transitioning to Regulatory Affairs. Currently, Samar is the Director of Regulatory Affairs at Boehringer-Ingelheim (Canada) Ltd., a global family owned Pharmaceutical Company. Samar’s proficiency includes over 25 years of experience in progressive roles in the Pharmaceutical Industry, with more than 18 years of proven strategic leadership and people management skills, motivating various teams in different functions to deliver high quality results in line with business priorities.
She graduated from the University of Western Ontario with a Master of Science degree in Molecular Biology, and most recently completed her Executive Master of Business Administration degree from the Ivey Business School in London Ontario.
Day 1: Oct 6, 2020
Streamlining the Path to Market: Regulatory Modernization – Is Canada a Land of Regulatory Obstacles or Opportunities?
The federal government has faced challenges in updating regulations to keep up with the modern changes to drug discovery and with market access. The result could be viewed as an onerous regulatory burden or as regulatory clarity paving the way for future opportunities. Take back to your team actionable insights about:
- The benefits expected from the current federal regulatory modernization project
- Whether perceived regulatory burdens can be alleviated or reduced
- How greater clarity in updated regulations can translate into opportunities for market access
Learn how to reduce regulatory burden and leverage regulatory modernization into increased opportunities
Day 2: Oct 7, 2020
Day 3: Oct 8, 2020